{"organizations": [], "uuid": "94ef9df5e3e6b61568884b13c557dd19bc82477b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bioverativ-says-regarding-terminat/brief-bioverativ-says-regarding-termination-of-merger-deal-with-sanofi-under-certain-circumstances-co-will-be-required-to-pay-fee-of-326-mln-idUSFWN1PH0O9", "country": "US", "domain_rank": 408, "title": "BRIEF-Bioverativ Says Regarding Termination Of Merger Deal With Sanofi Under Certain Circumstances Co Will Be Required To Pay Fee Of $326 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T15:41:00.000+02:00", "replies_count": 0, "uuid": "94ef9df5e3e6b61568884b13c557dd19bc82477b"}, "author": "", "url": "https://www.reuters.com/article/brief-bioverativ-says-regarding-terminat/brief-bioverativ-says-regarding-termination-of-merger-deal-with-sanofi-under-certain-circumstances-co-will-be-required-to-pay-fee-of-326-mln-idUSFWN1PH0O9", "ord_in_thread": 0, "title": "BRIEF-Bioverativ Says Regarding Termination Of Merger Deal With Sanofi Under Certain Circumstances Co Will Be Required To Pay Fee Of $326 Mln", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sec", "sentiment": "none"}, {"name": "mln reuters staff", "sentiment": "none"}, {"name": "sanofi under certain circumstances co", "sentiment": "none"}, {"name": "bioverativ inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News  42 PM / Updated 14 minutes ago BRIEF-Bioverativ Says Regarding Termination Of Merger Deal With Sanofi Under Certain Circumstances Co Will Be Required To Pay Fee Of $326 Mln Reuters Staff 1 Min Read \nJan 22 (Reuters) - Bioverativ Inc: \n* BIOVERATIV SAYS REGARDING TERMINATION OF MERGER DEAL WITH SANOFI UNDER CERTAIN CIRCUMSTANCES CO WILL BE REQUIRED TO PAY FEE OF $326 MILLION - SEC FILING Source text: ( bit.ly/2DC3sg7 ) Further company coverage:", "external_links": [], "published": "2018-01-22T15:41:00.000+02:00", "crawled": "2018-01-22T16:02:09.022+02:00", "highlightTitle": ""}